A Phase 3 interventional study of Colchicine and Local standard of care in COVID-19, sponsored by Estudios Clínicos Latino América. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-27.
Sponsored by Estudios Clínicos Latino América · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in COVID-19 with a site in Argentina — 6 open to participants now, 7 under way, 5 of them phase 3. COVID-19 · Argentina.
Among the 127 studies in COVID-19 with a site in Argentina, this one is the 29th largest by enrollment of the 87 interventional ones that give a count, is one of 70 that started in 2020, is one of 35 in phase 3, and was the 2nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 127 studies in COVID-19 with a site in Argentina are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in Argentina, United States, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
Pfizer · Sites in Argentina, United States, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in Argentina, United States, Belgium and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Argentina, United States, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in Argentina, United States, Australia and 36 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 42 · Phase 3 54 · Phase 4 4
First in 2020; this study’s year is marked. 70 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,279 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 414 across the 87 interventional studies, 503 across the 40 observational. Of the 102 that completed or were terminated, 41 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Estudios Clínicos Latino América is the lead sponsor of 3 studies on the registry; none are open to participants now.
Estudios Clínicos Latino América has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in Argentina that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 127 studies in COVID-19 with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement for mechanical ventilation.
Various anti-viral treatments are being tested in clinical trials worldwide. The World Health Organization (WHO) launched a simple,pragmatic worldwide open-label trial to test Remdesivir, Lopinavir/Ritonavir, Interferon and Hydroxychloroquine or Chloroquine.The most important complication of COVID-19 severe cases is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality. Accumulating evidence suggests that patients with severe COVID-19 might have a cytokine storm syndrome, a hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinemia and multiorgan failure.
The proposed pathophysiological mechanism of cytokine storm and inflammatory cascade activation is based on evidence collected primarily during the SARS-CoV and MERS-CoV epidemics (with a significant increase in IL1B, IL6, IL12, IFNγ, IP10, TNFα, IL15, and IL17 among others). The data collected during the pandemic with COVID-19 also shows a significant increase in inflammatory cytokines (GCSF, IP10, MCP1, MIP1A, and TNFα, among others) in sicker patients admitted to intensive care. In the absence of effective treatments for the management of patients with COVID-19 and respiratory failure, the immunomodulatory and anti-inflammatory effect of colchicine on cytokines involved in the hyper-inflammatory state is postulated. Several lines of research worldwide are testing powerful anti-inflammatory drugs for the pandemic, with different options including steroids, cytokine blockers, and other potent anti-inflammatory agents. Steroids are partially contraindicated in viral infections.
Colchicine is a powerful anti-inflammatory drug approved for the treatment or prevention of gout and Familial Mediterranean Fever at doses ranging between 0.3 mg and 2.4 mg/day. Its mechanism of action is through the inhibition of tubulin polymerization, as well as through potential effects on cellular adhesion molecules and inflammatory chemokines. It might also have direct anti-inflammatory effects by inhibiting key inflammatory signalling networks known as inflammasome and pro-inflammatory cytokines. Additionally, evidence suggests that colchicine exerts a direct anti-inflammatory effect by inhibiting the synthesis of tumor necrosis factor alpha and IL-6, monocyte migration, and the secretion of matrix metalloproteinase-9. Through the disruption of the cytoskeleton, colchicine is believed to suppress secretion of cytokines and chemokines as well as in vitro platelet aggregation. All these are potentially beneficial effects that might diminish or ameliorate the COVID-19 inflammatory storm associated with severe forms of the disease. Importantly, in one contemporary trial low-dose colchicine administered to patients who survived from acute coronary syndrome shows a statistically significantly reduction of cardiovascular complications.
We have therefore designed in a simple, pragmatic randomized controlled trial to test the effects of colchicine on severe hospitalized COVID-19 cases with the aim of reducing mortality.
Sample size calculation:
A minimum sample size of 1200 patients will provide 80% power to detect a relative risk reduction of approximately 30% in the treated group if the assumed composite rate (new requirement of intubation and / or death) in the control group is about 24%.
The ECLA PHRI COLCOVID Trial allows randomization to another trial, specifically patients included in the trial might be (or not) randomized to an antithrombotic strategy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SARS (severe acute respiratory syndrome)
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local standard of care plus colchicine (specific dosage schedule)
Drug: Colchicine · Other: Local standard of care
Local standard of care for COVID-19 SARS moderate / high-risk patients
Other: Local standard of care
The colchicine dosage schedule will vary according to the following scenarios: 1. In patients not receiving Lopinavir/Ritonavir * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1) * The next day 0.5 mg bid for 14 days or until discharge. 2. In patients receiving Lopinavir/Ritonavir * Loading dose of 0.5 mg (day 1) * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge. 3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir. * Continue with 0.5 mg every 72 hours for 14 days or until discharge. Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.
Also known as: Colchicina
Local standard of care for COVID-19 SARS moderate /high-risk patients
Composite outcome: New requirement for mechanical ventilation or death
Number of participants who require new intubation for mechanical ventilation or die
Time frame: 28 days post randomization
Mortality
Number of participants who die
Time frame: 28 days post randomization
New requirement for mechanical ventilation or death from respiratory failure
Number of participants who require new intubation for mechanical ventilation or die from respiratory failure
Time frame: 28 days post randomization
New requirement for mechanical ventilation or death from non-respiratory failure
Number of participants who require new intubation for mechanical ventilation or die from non-respiratory failure
Time frame: 28 days post randomization
Mortality due to respiratory failure
Number of participants who die from respiratory failure
Time frame: 28 days post randomization
Mortality due to non-respiratory failure
Number of participants who die from non-respiratory failure
Time frame: 28 days post randomization
In hospital - Composite outcome
Number of participants who require intubation for mechanical ventilation or die
Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days
In hospital - Mortality
Number of participants who die
Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days
Composite outcome (New requirement for mechanical ventilation or death) evaluated in Non-intubated population
Number of participants who were not intubated at randomization and require new intubation for mechanical ventilation or die
Time frame: 28 days post randomization
Mortality evaluated in Non-intubated population
Number of participants who were not intubated at randomization and die
Time frame: 28 days post randomization
Mean WHO descriptive score of COVID-19 during hospitalization
Mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group
Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days
Highest WHO descriptive score of COVID-19 during hospitalization
Mean highest WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group
Time frame: During hospitalization or until death, whichever comes first, assessed up to 28 days
Plan to share: No
Ran from Apr 2020 to primary completion in Apr 2021, 12 months.
Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 12 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Estudios Clínicos Latino América